18F-FDG PET/CT: Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients

Sara Sheikhbahaei, Esther Mena, Charles Marcus, Rick Wray, Mehdi Taghipour, Rathan M. Subramaniam

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the value of an 18F-FDG PET/CT-based interpretation system (Hopkins criteria) to assess the therapy response and survival in lung cancer. Methods: This is an Institutional Review Board-approved, retrospective study. A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessment 18F-FDG PET/CT within 6 mo (mean, 7.5 wk) of completion of treatment, were included. Patients were primarily treated with surgical resection, chemotherapy, radiation therapy, or a combination of these treatments. PET/CT studies were interpreted by 2 nuclear medicine physicians, and discrepancies were resolved by a third interpreter. The studies were scored using a qualitative 5-point scale for the primary tumor, mediastinum, distant metastatic site, if present, and overall assessment. Scores 1, 2, and 3 were considered negative and scores 4 and 5 were considered positive for residual disease. Patients were followed for a median of 12 mo (up to 128 mo). Kaplan-Meier plots with a Mantel-Cox log-rank test were performed considering death as the endpoint. Results: Overall, the PET/CT studies were positive in 144 (71.6%) and negative in 57 (28.4%) patients. There was substantial agreement between 2 interpreters (R1, R2), with a κ of 0.78 (P < 0.001). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Hopkins scoring system were 89%, 80%, 92.8%, 71.4%, and 86.7%, respectively. Overall, PET/CT resulted in starting a new treatment plan in 70.8%of patients with positive residual disease on therapy assessment PET/CT. There was a significant difference in overall survival (OS) between patients who were categorized as positive in comparison to those who were categorized as negative (hazard ratio [HR] = 2.12; 95% confidence interval = 1.44-3.12), which remained significant after adjustment for disease stage, prior clinical suspicion, and primary treatment. Subgroup analysis according to the tumor histology showed that positive Hopkins scoring could significantly predict the OS in both small cell lung cancer (HR = 2.88; log-rank, P = 0.02) and non-small cell lung cancer (HR = 2.01; log-rank, P = 0.001). Similarly, there was a significant difference in OS between patients with positive and negative Hopkins score both in those who had surgical resection as part of the primary treatment (HR = 6.09; log-rank, P < 0.001) and in those who were treated with chemotherapy with or without radiation (HR = 1.60; log-rank, P = 0.02). Conclusion: The 5-point qualitative therapy response interpretation for lung cancer has substantial interinterpreter agreement and high accuracy and could significantly predict survival in lung cancer, irrespective of tumor histology and treatment modality.

Original languageEnglish (US)
Pages (from-to)855-860
Number of pages6
JournalJournal of Nuclear Medicine
Volume57
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Fluorodeoxyglucose F18
Lung Neoplasms
Survival
Therapeutics
Histology
Drug Therapy
Neoplasms
Research Ethics Committees
Nuclear Medicine
Small Cell Lung Carcinoma
Mediastinum
Non-Small Cell Lung Carcinoma
Radiotherapy
Retrospective Studies
Confidence Intervals
Radiation
Physicians
Biopsy
Sensitivity and Specificity

Keywords

  • Lung cancer
  • PET/CT
  • Survival
  • Therapy assessment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT : Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients. / Sheikhbahaei, Sara; Mena, Esther; Marcus, Charles; Wray, Rick; Taghipour, Mehdi; Subramaniam, Rathan M.

In: Journal of Nuclear Medicine, Vol. 57, No. 6, 01.06.2016, p. 855-860.

Research output: Contribution to journalArticle

Sheikhbahaei, Sara ; Mena, Esther ; Marcus, Charles ; Wray, Rick ; Taghipour, Mehdi ; Subramaniam, Rathan M. / 18F-FDG PET/CT : Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients. In: Journal of Nuclear Medicine. 2016 ; Vol. 57, No. 6. pp. 855-860.
@article{f55cc60837f0408cb6d97648beaabf1f,
title = "18F-FDG PET/CT: Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients",
abstract = "The purpose of this study was to evaluate the value of an 18F-FDG PET/CT-based interpretation system (Hopkins criteria) to assess the therapy response and survival in lung cancer. Methods: This is an Institutional Review Board-approved, retrospective study. A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessment 18F-FDG PET/CT within 6 mo (mean, 7.5 wk) of completion of treatment, were included. Patients were primarily treated with surgical resection, chemotherapy, radiation therapy, or a combination of these treatments. PET/CT studies were interpreted by 2 nuclear medicine physicians, and discrepancies were resolved by a third interpreter. The studies were scored using a qualitative 5-point scale for the primary tumor, mediastinum, distant metastatic site, if present, and overall assessment. Scores 1, 2, and 3 were considered negative and scores 4 and 5 were considered positive for residual disease. Patients were followed for a median of 12 mo (up to 128 mo). Kaplan-Meier plots with a Mantel-Cox log-rank test were performed considering death as the endpoint. Results: Overall, the PET/CT studies were positive in 144 (71.6{\%}) and negative in 57 (28.4{\%}) patients. There was substantial agreement between 2 interpreters (R1, R2), with a κ of 0.78 (P < 0.001). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Hopkins scoring system were 89{\%}, 80{\%}, 92.8{\%}, 71.4{\%}, and 86.7{\%}, respectively. Overall, PET/CT resulted in starting a new treatment plan in 70.8{\%}of patients with positive residual disease on therapy assessment PET/CT. There was a significant difference in overall survival (OS) between patients who were categorized as positive in comparison to those who were categorized as negative (hazard ratio [HR] = 2.12; 95{\%} confidence interval = 1.44-3.12), which remained significant after adjustment for disease stage, prior clinical suspicion, and primary treatment. Subgroup analysis according to the tumor histology showed that positive Hopkins scoring could significantly predict the OS in both small cell lung cancer (HR = 2.88; log-rank, P = 0.02) and non-small cell lung cancer (HR = 2.01; log-rank, P = 0.001). Similarly, there was a significant difference in OS between patients with positive and negative Hopkins score both in those who had surgical resection as part of the primary treatment (HR = 6.09; log-rank, P < 0.001) and in those who were treated with chemotherapy with or without radiation (HR = 1.60; log-rank, P = 0.02). Conclusion: The 5-point qualitative therapy response interpretation for lung cancer has substantial interinterpreter agreement and high accuracy and could significantly predict survival in lung cancer, irrespective of tumor histology and treatment modality.",
keywords = "Lung cancer, PET/CT, Survival, Therapy assessment",
author = "Sara Sheikhbahaei and Esther Mena and Charles Marcus and Rick Wray and Mehdi Taghipour and Subramaniam, {Rathan M.}",
year = "2016",
month = "6",
day = "1",
doi = "10.2967/jnumed.115.165480",
language = "English (US)",
volume = "57",
pages = "855--860",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - 18F-FDG PET/CT

T2 - Therapy response assessment interpretation (Hopkins criteria) and survival outcomes in lung cancer patients

AU - Sheikhbahaei, Sara

AU - Mena, Esther

AU - Marcus, Charles

AU - Wray, Rick

AU - Taghipour, Mehdi

AU - Subramaniam, Rathan M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The purpose of this study was to evaluate the value of an 18F-FDG PET/CT-based interpretation system (Hopkins criteria) to assess the therapy response and survival in lung cancer. Methods: This is an Institutional Review Board-approved, retrospective study. A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessment 18F-FDG PET/CT within 6 mo (mean, 7.5 wk) of completion of treatment, were included. Patients were primarily treated with surgical resection, chemotherapy, radiation therapy, or a combination of these treatments. PET/CT studies were interpreted by 2 nuclear medicine physicians, and discrepancies were resolved by a third interpreter. The studies were scored using a qualitative 5-point scale for the primary tumor, mediastinum, distant metastatic site, if present, and overall assessment. Scores 1, 2, and 3 were considered negative and scores 4 and 5 were considered positive for residual disease. Patients were followed for a median of 12 mo (up to 128 mo). Kaplan-Meier plots with a Mantel-Cox log-rank test were performed considering death as the endpoint. Results: Overall, the PET/CT studies were positive in 144 (71.6%) and negative in 57 (28.4%) patients. There was substantial agreement between 2 interpreters (R1, R2), with a κ of 0.78 (P < 0.001). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Hopkins scoring system were 89%, 80%, 92.8%, 71.4%, and 86.7%, respectively. Overall, PET/CT resulted in starting a new treatment plan in 70.8%of patients with positive residual disease on therapy assessment PET/CT. There was a significant difference in overall survival (OS) between patients who were categorized as positive in comparison to those who were categorized as negative (hazard ratio [HR] = 2.12; 95% confidence interval = 1.44-3.12), which remained significant after adjustment for disease stage, prior clinical suspicion, and primary treatment. Subgroup analysis according to the tumor histology showed that positive Hopkins scoring could significantly predict the OS in both small cell lung cancer (HR = 2.88; log-rank, P = 0.02) and non-small cell lung cancer (HR = 2.01; log-rank, P = 0.001). Similarly, there was a significant difference in OS between patients with positive and negative Hopkins score both in those who had surgical resection as part of the primary treatment (HR = 6.09; log-rank, P < 0.001) and in those who were treated with chemotherapy with or without radiation (HR = 1.60; log-rank, P = 0.02). Conclusion: The 5-point qualitative therapy response interpretation for lung cancer has substantial interinterpreter agreement and high accuracy and could significantly predict survival in lung cancer, irrespective of tumor histology and treatment modality.

AB - The purpose of this study was to evaluate the value of an 18F-FDG PET/CT-based interpretation system (Hopkins criteria) to assess the therapy response and survival in lung cancer. Methods: This is an Institutional Review Board-approved, retrospective study. A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessment 18F-FDG PET/CT within 6 mo (mean, 7.5 wk) of completion of treatment, were included. Patients were primarily treated with surgical resection, chemotherapy, radiation therapy, or a combination of these treatments. PET/CT studies were interpreted by 2 nuclear medicine physicians, and discrepancies were resolved by a third interpreter. The studies were scored using a qualitative 5-point scale for the primary tumor, mediastinum, distant metastatic site, if present, and overall assessment. Scores 1, 2, and 3 were considered negative and scores 4 and 5 were considered positive for residual disease. Patients were followed for a median of 12 mo (up to 128 mo). Kaplan-Meier plots with a Mantel-Cox log-rank test were performed considering death as the endpoint. Results: Overall, the PET/CT studies were positive in 144 (71.6%) and negative in 57 (28.4%) patients. There was substantial agreement between 2 interpreters (R1, R2), with a κ of 0.78 (P < 0.001). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Hopkins scoring system were 89%, 80%, 92.8%, 71.4%, and 86.7%, respectively. Overall, PET/CT resulted in starting a new treatment plan in 70.8%of patients with positive residual disease on therapy assessment PET/CT. There was a significant difference in overall survival (OS) between patients who were categorized as positive in comparison to those who were categorized as negative (hazard ratio [HR] = 2.12; 95% confidence interval = 1.44-3.12), which remained significant after adjustment for disease stage, prior clinical suspicion, and primary treatment. Subgroup analysis according to the tumor histology showed that positive Hopkins scoring could significantly predict the OS in both small cell lung cancer (HR = 2.88; log-rank, P = 0.02) and non-small cell lung cancer (HR = 2.01; log-rank, P = 0.001). Similarly, there was a significant difference in OS between patients with positive and negative Hopkins score both in those who had surgical resection as part of the primary treatment (HR = 6.09; log-rank, P < 0.001) and in those who were treated with chemotherapy with or without radiation (HR = 1.60; log-rank, P = 0.02). Conclusion: The 5-point qualitative therapy response interpretation for lung cancer has substantial interinterpreter agreement and high accuracy and could significantly predict survival in lung cancer, irrespective of tumor histology and treatment modality.

KW - Lung cancer

KW - PET/CT

KW - Survival

KW - Therapy assessment

UR - http://www.scopus.com/inward/record.url?scp=84973594978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973594978&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.165480

DO - 10.2967/jnumed.115.165480

M3 - Article

C2 - 26837337

AN - SCOPUS:84973594978

VL - 57

SP - 855

EP - 860

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -